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Cystic fibrosis (CF) is one of the most common genetic lung diseases caused by a mutation of the 
chloride regulator in airway cells, which leads to dysregulation of iron transport and airway 
dehydration. As a result, airway mucus in CF patients (i.e. CF sputum) is highly viscoelastic and 
hard to be cleared by physiological mucus clearance mechanism, thereby promoting chronic 
infection and inflammation. Previously, bacteria cell growth and neutrophil-mediated bacterial cell 
killing were studied with mucus solution prepared with different concentration of mucin which is 
the major macromolecular component of airway mucus. However, mucus solution does not 
recapitulate airway mucus on the account of failure to form physiological gel-like structures 
relevant to behaviors of bacteria and neutrophils. Thus, to investigate the effect of microstructure 
of mucus on these behaviors on the cellular and molecular levels, we developed artificial 
irreversible and bio-reducible mucus hydrogel with well-defined pore sizes and similar 
biochemical contents comparable to CF airway mucus, by chemically crosslinking porcine gastric 
mucin (PGM). Since CF patients are often treated with mucus-altering agents (i.e. mucolytics) to 
reduce the viscoelasticity of mucus, we not only evaluated the microstructure of artificial mucus 
hydrogel per se but also examined the mucolytic-mediated microstructural changes using multiple 
particle tracking method. The results here show that the microstructure and mucolytic-mediated 
microstructure changes of artificial bio-reducible mucus hydrogels are comparable to what were 
observed in CF sputum. And we also confirmed that bulk rheology of bio-reducible artificial 
mucus is comparable to that of CF sputum. In addition, mucolytic-mediated changes in bulk 
rheology properties of the mucus hydrogel and CF sputum were virtually identical. Furthermore, 
we investigated the biochemical properties of bio-reducible mucus hydrogel (i.e. mucin and, 
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cysteines content), and lastly, the ability of bacteria to grow in artificial bio-reducible mucus 
hydrogel. These results show that the artificial bio-reducible mucus hydrogel is a promising model 
to investigate the effect of mucus microstructure on mucosal pathogenesis and innate immunity in 
CF airways. 
Advisor: Dr. Jung Soo Suk 
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1.1 The structure and function of airway mucus  
Mucus provides a physiological barrier to environmental toxins and pathogens and is one of the 
first lines of innate immune defense in the conducting airway epithelium [1]–[4]. Normal mucus 
clearance is mediated by a two-phase liquid system that interfaces with beating cilia [5]. The upper 
phase is a mucus layer, which is a polymeric network that has bulk viscoelastic physical 
characteristics despite being made up of ~97% water. Thus, mucus is a polymeric gel with both 
fluid and solid properties, such as soft, elastic and viscous [3], [6]–[9]. The composition of normal 
mucus are 97% water and 3% solids (mucins, non-mucin proteins, salts, lipids and cellular debris). 
Mucins are exceedingly large glycoproteins, the monomer of which is typically 10-40 MDa in size 
and 0.2-0.6 µm and linked together by disulfide bonds. The multimers are like long flexible strings 
densely coated with O-linked N-acetyl galactosamine and N-linked sulfate-bearing glycans, which 
are negatively charged [7], [10]–[15]. These glycosylated and highly hydrophilic regions are 
separated by hydrophobic regions that fold into hydrophobic globules which stabilized by multiple 
internal cysteines-rich domains [7], [10]–[15]. Five of the secreted mucins have terminal cysteine 
rich domains that can form disulfide bonds resulting in polymers that impart the properties of a 
gel. Two of these polymers, MUC5AC and MUC5B, are highly expressed in the airways [7], [9], 
[15]. They form the mucus gel both by network entanglement and by noncovalent calcium-
dependent cross-linking of adjacent polymers [6], [13]. Since the mucin chain can bind to large 
amounts of water, this can act as a liquid reservoir for periciliary layer [16]. The hydration of 
mucus significantly affects the viscosity and elasticity of mucus, which in turn determines the 
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ciliary action and the clearance effect of mucus [3], [6], [8], [13], [16], [17]. However, excessive 
secretion of mucin or maladjustment of surface fluid volume hinders clearance of mucus and 
increased mucus elasticity [3], [6], [8].  
1.2 Cystic Fibrosis 
Cystic fibrosis (CF) is one of the most common inherited chronic disease that affects nearly 30,000 
individuals in United States [18]. A hallmark of CF is chronic respiratory infection, which may 
start very early in the life of these patients. And much of morbidity and mortality associated with 
CF is related to the pulmonary system, primarily the upper and lower airways and ultimately 
leading to premature death in 90% of patients [19], since CF is caused by mutations in the CF 
transmembrane conductance regulator (CFTR) gene, which encodes the main anion channel 
expressed in the epithelium [20]. The most accepted hypothesis is that the mutation of CFTR 
causes a defect in CFTR proteins, and thus, a lack of transport of chloride and accompanying water 
across the airway epithelium. Then, excessive sodium reabsorption lead to dehydration of airway 
surface fluid and impaired mucociliary clearance. The resulting increased viscosity of mucus result 
in the inability of clearing secretions, which leads to chronic infection, inflammation and 
irreparable mucus clearance [5], [18], [21], [22]. Even patients that are treated with antibiotics and 
mucolytics that modify properties of mucus still suffer from irreparable lung damage. 
1.3 The formation of pathologic mucus 
In patients with cystic fibrosis, MUC 1, 2, 5AC and 5B are translated and MUC5AC and MUC5B 
products have been demonstrated to be the major components in airway mucins [23]. The 
characteristics of CF mucus are neutrophil infiltration, high concentrations of neutrophil-derived 
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DNA and actin filaments [9], [24]; infection with organisms such as Pseudomonas aeruginosa, 
Staphylococcus aureus, and aspergillus species, often form biofilms at the epithelial-cell surface.  
The dehydrated, highly entangled polymeric macromolecule that forms a gel matrix with a reduced 
pore size from about 500 nm to about 150 nm [3]. The reduction in pore size lead to immobilize 
the microorganisms in the mucus gel, thereby improving the formation of biofilms and inhibiting 
the movement of neutrophils that prevents clearing the infection [25]. The effects of these 
processes are manifested (a) radiographically as bronchiectasis, (b) pathologically as neutrophilic 
inflammation, airway fibrosis, (c) increased numbers of mucin-secreting cells, especially in the 
submucosal glands, (d)clinically as cough, purulent sputum, recurrent lung infections, and (e) rapid 
loss of lung function [26]–[28]. 
1.4 Recent progress in CF mucus study 
To investigate the effect of airway surface liquid (ASL) hyperabsorption on bacteria biofilm 
formation, Matsui, etc. used normal (2.5% solids wt/wt) and CF-liked (8%) concentrations of 
mucus which obtained from well differentiated human airway cultures as model to mimic the 
interaction of inhaled bacteria with a central feature of the CF lung. By investigating bacteria 
microcolony development, they found that the concentrated mucus (8%) generates a unique 
environment in which bacteria are confined spatially so that the capacity of bacteria to leave the 
site by their normal means of motility is restrained [29]. They also investigated the ability of 
neutrophil capture and killing bacteria by similar model. Furthermore, they found that in CF-like 
concentrated mucus (6.5%) harvested from in vitro airway epithelial cells, the ability of neutrophil 
capture and killing bacteria are suppressed [30]. However, they mainly focused on the bulk 
property of mucus as in mucus concentration (e.g. % solids contents).  
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In our previous study, it was proved that the microrheological and microstructural properties of 
human mucus secretions can be assessed by monitoring the diffusion rates of muco-inert 
nanoparticle (MIP) probes, also referred to as mucus-penetrating particles (MPP) in our prior 
studies [8], [31]–[33]. MIP with diameters smaller than mucus mesh spacings are capable of 
efficiently penetrating sputum since dense surface coatings with polyethylene glycol (PEG) render 
the particle surface muco-inert. MIP transport in mucus is primarily hindered by physical 
obstruction imposed by the mucus mesh structure rather than adhesive interactions [33], [34]. 
Duncan GA, et al., correlated patient-specific sputum microstructural properties and solids content 
with clinical status, FEV1 (i.e. the maximal amount of air you can forcefully exhale in one second). 
And they found that percent solids content which did not significantly corelate well with FEV1, 
however, the microstructures of mucus Log10 (median MSD1s) were positively and significantly 
correlated with measured FEV1 [21].  
1.5 Motivation  
Mucus hypersecretion and airway dehydration lead to pulmonary exacerbation associated with 
polymicrobial infection both virus and bacteria, which means that a CF patient at particular point 
of time may be infected with a number of different organisms. And the phenotype of bacteria like 
Pseudomonas aeruginosa may also change from non-mucoidal to mucoidal state when patients 
have been infected for a prolonged period of time [19]. Thus, duo to the complex 
microenvironment in CF airway mucus, it is hard for researchers to understand the behavior of 
bacteria and the distribution of inflammatory cells based on effect of microstructure. Thus, in order 
to get better understanding of bacteria behavior and inflammatory cell distribution, it is necessary 
to develop an artificial mucus hydrogel to mimic CF patients’ sputum not only from solids content 
but also from microstructure features.  
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Thus, in this study, we developed both irreversible and bio-reducible artificial mucus hydrogel to 
mimic CF airway mucus by crosslinking mucin from porcine stomach with different crosslinkers. 
We further assessed the microstructure of artificial mucus hydrogel with different crosslinking 
density, evaluated the mucolytics-mediated microstructure changes, and bulk rheology changes of 
artificial mucus hydrogel compared with that of CF airway mucus. We also examined the 
biochemical components such as the mucin content and disulfide bonds (e.g. cysteine 
concentration) in artificial hydrogel. We compared these components with those found in CF 
airway mucus. These results will establish a promising model to investigate the effect of mucus 
microstructure on pathogenesis and inflammatory cells transport. 
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Materials and Methods 
2.1 Develop artificial mucus hydrogel model  
For non-bio-reducible artificial hydrogel model, pig gastric mucin (PGM) solutions were prepared 
by dissolving PGM (Porcine gastric mucin, Sigma-Aldrich) with buffer solution containing 
154mM NaCl, 3mM CaCl2, and 15mM NaH2PO4 at pH 7.4 and were rapidly mixed for 2 hours 
using a magnetic stir plate to achieve concentration of 10% (w/v). MW 1000 SC-PEG-SC 
(Biochempeg Scientific Inc.) which contain NHS ester at two arms at varying final concentrations 
were added dropwise to PGM solutions to achieve a final concentration of 5% (w/v). The solution 
was mixed by pipetted several times. And the mixed solution was incubated overnight in the shaker 
at 37°C, 225 RPM to allow cross-linking to occur. The cross-linked mucus hydrogel was 
subsequently collected by centrifugation at 17, 000 g for 1 hour. The supernatant was removed, 
and the pellet was then flash frozen in liquid N2 and lyophilized overnight. The lyophilized, cross-
linked mucus hydrogels were reconstituted to the final overall solids content of 5% in the original 
buffer solution and then the hydrogels swelled for 24 hours before being used. 
For bio-reducible artificial hydrogel model, hydrogels mainly composed of PGM were prepared 
by addition of MW 2000 OPSS-PEG-OPSS (Laysan Bio, Lnc.). PGM solution with concentration 
of 10%, 20% 30% and 40% were prepared with same way.  The PGM solutions with different 
concentrations were treated with Dithiothreitol (DTT) (Sigma-Aldrich). The molar ratio of 
disulfide bonds in PGM solution and DTT is 1:2. The solutions were mixed by vertexing at the 
highest speed for 1 min. The mixed solutions were incubated at 37°C water bath for 2 hours to 
break the disulfide bonds. OPSS-PEG-OPSS was dissolved with original buffer solution and then 
mixed into PGM solution. The molar ratio of OPSS-PEG-OPSS and thiol group is 2:1. After mixed 
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by pipetted several times and quickly vortexed, the mixed solutions were incubated in 37°C shaker 
with shaking at 225 RPM for 48 hours to allow cross-linking to occur. The pellets were 
subsequently collected by centrifugation at 17, 000 g for 1 hour and the supernatant was removed. 
The pellet was then flash frozen in liquid N2 and lyophilized overnight. The lyophilized, cross-
linked mucus hydrogels were reconstituted to the final overall solids content of 5% in the original 
buffer solution and then the hydrogels swelled for 24 hours before used. 
2.2 Develop mucus-inert nanoparticle (MIP) 
Fluorescent, carboxylate-modified polystyrene spheres (PS-COOH) with 100 nm diameter 
(Molecular Probes) were coated by covalently with 5 KDa methoxy-PEG-amine (Creative 
PEGWorks) using carbodiimide coupling chemistry. The PS-COOH particles were sonicated for 
10 min prior to aliquoting. The aliquoted particles were diluted 4-fold in ultrapure water and then 
were sonicated for 7 min. PEG 5K-NH2 were added 2-fold excess to the particle suspension. After 
mixing the suspension solution and dissolving the PEG-NH2, N-hydrooxysulfosuccinimide 
sodium salt (sulfo-NHS, Sigma-Aldrich) was added and quickly dissolved by vertexing. The 
mixed solution was diluted 5 times by 200mM borate buffer, pH 8.2. 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC, Invitrogen) was added immediately and 
mixed by vertexing. The mixed solution was incubated at room temperature and mixed for at least 
12 hours. After incubation, the particle solution was dialyzed in ultrapure water for 24 hours by 
using the Spectra/Por Dialysis membrane MWCO: 100KD (Biotech CE Tubing) to remove 
byproducts. The dialyzed particle solution was collected and lyophilized overnight. The particle 
pellet was resuspended to achieve solid content 2%. The modified particles were stored in 4°C 
fridge before using.  
8 
 
2.3 Particle characterization and stability test   
Particle characterization: PS particles and PSPEG particles were diluted in 10 mM NaCl at pH 7.4, 
and then added in to pre-washed disposable folded capillary cells (Malvern) for zeta potential and 
UV-transparent disposable cuvettes (Sarstedt, Int.) for hydrodynamic diameter and polydispersity 
index (PDI). The zeta potential and size were tested using Zatasizer Nano ZS90. 
Particle stability test: PGM solution with different concentration was made with the original buffer 
solution. The PEG coated particles PSPEG and non-coated particles PS were diluted 1000 times 
with PGM solution. The solutions were mixed by sonicated 5 min. Then 150 µL mixed particle 
solution were added in the UV-transparent disposable cuvettes (Sarstedt, Int.). the size of each 
particles was measured at different time points by using Zetasizer Nano ZS90 (Malvern 
Instruments), at 137° scattering angle. 
2.4 Human specimens  
Spontaneously expectorated CF sputum samples were collected from patients at the adult CF clinic 
at Johns Hopkins University. And the microstructures of CF sputum samples were characterized 
within 24 hours, since after 24 hours the microstructures of sputum samples would change 
significantly because of degradation of mucins. And the rest of CF sputum samples used for 
biochemical properties analysis were stored in -80°C freezers.  
2.5 Characterize artificial mucus hydrogel and CF sputum with and without 
mucolytics treatment 
Ten microliter aliquots of hydrogels were dispensed in custom microscopy slides using positive-
displacement pipette (Gilson, Inc.). Next, 0.5 µL of pre-mixed PSPEG and PS particles with 
concentration of 0.002% and 0.0002% were dispersed gently in the hydrogel and CF sputum 
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samples. Also, to test the effect of mucolytic on hydrogel and CF sputum samples, 0.5 µL TCEP 
or 0.5 µL NAC were added into hydrogel to achieve 10-20 mM final concentration of mucolytics. 
The slides were sealed with a small coverslip to prevent evaporation and the slides were incubated 
for 30 min to 1 hour and avoiding the light. Samples were imaged at room temperature using an 
Axio Observer inverted epifluorescence microscope and ×100/1.46 NA oil-immersion objective 
with image resolution of 25 nm/pixel (Zeiss). To avoid edge effects due to the presence of glass 
coverslips, images were taken centrally within the sample approximately 2 μm away from the 
bottom coverslip. Videos were recorded at a frame rate of 15 Hz for 300 frames, using an EM-
CCD camera (Evolve 512; Photometrics). For each sample, 3–5 videos were collected. 
2.6 Multiple particles tracking analysis 
Motions of nanoparticles were captured at 15 frames per second (i.e. exposure time of 67 ms) for 
20 seconds and MetaMorph software (Molecular Devices, San Jose, CA) were used. The time-
averaged mean squared displacement (MSD) values are averaged squared distances travelled by 
individual particles at a given time interval (i.e. timescale in seconds) and thus are directly 
proportional to particle diffusion rates. The analysis was performed using automated software 
written in MATLAB (Mathworks), based on a previously developed algorithm. Briefly, the x and 
y positions of nanoparticle centers were determined based on an intensity threshold. Trajectories 
of particles were constructed by connecting particle centers of all images and obtaining the moving 
distance between each frame. The time-averaged mean squared displacement [MSD(τ)] can be 
calculated for each particle trajectory: <Δr2(τ)> = < [x(t + τ)-x(t)]2 + [y(t + τ)-y(t)]2 >, where τ is 
the time lag between frames. The median values were determined based on measured MSD for 
individual particle. Also, we have found previously that when MSD measured at τ = 1s (e.g. 
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MSDτ=1s), the static error does not cause significant effects on calculated MSD values. Based on 
this, Log10(median MSDτ=1s) was used as our primary readout for evaluating hydrogel pore size. 
2.7 Particle-tracking microrheology analysis 
The viscoelastic properties of hydrogels can be determined using the generalized Stokes-Einstein 
relation, which has been successfully used in prior studies of CF sputum, which relates the 
viscoelastic spectrum [G(s)] to the Laplace transform of <Δr2(τ)>, <Δr2(s)>, with the equation G(s) 
= 2kBT/[πas<Δr
2(s)>] by assuming that the local viscoelastic modulus around a sphere is the same 
as the macroscopic viscoelastic modulus, where kBT is thermal energy, a is particle radius, and s 
is the complex Laplace frequency, s = i ω, in which i is a complex number and ω is frequency. 
Based on this, the complex modulus can be calculated as G*(ω) = G’(ω) + G”(iω) defined by 
storage modulus and loss modulus which given by Gr(t). The elastic modulus per blob is in an 
order of kBT, where kB is the Boltzmann constant and T is the absolute temperature. In polymer 
gels, the elastic blob is considered to be equal to the geometric blob (the size of the average distance 
between the crosslinkers or branch points); the polymer chains between crosslinkers are the 
elastically effective chains. The net elastic modulus (G’) of the gel is written as the product of 
number density of elastic blob (ρel), the elastic modulus per blob is: G’ = ρelkBT. By assuming a 
cubic lattice for simplicity, the size of elastic blob is given as: ξel= ρel
−1/3. Thus, the pore size of 
the sputum hydrogel (ξ) can be estimated based on measured G’ as ξ ≈ (kBT/G′)
1/3 [35]–[38]. The 
microviscosity and pore size values were determined from individual PSPEG trajectories rather 





2.8 Examine the rheology of bio-reducible mucus hydrogel 
Rheological measures were derived from a MCR 302 Rheometer (Anton Paar Germany GmbH) 
with 8 mm roughened flat plate geometry set at a gap height of 150 microns. An aliquot of 25 
microliters of mucin hydrogel was placed between plates with the following procedures. For TCEP 
experiments, the gel was pre-incubated with 10-20 mM TCEP for 30 minutes before recording the 
data using Rheoplus V3.6 software (Anton Paar). An amplitude sweep was performed on each 
hydrogel to determine an appropriate strain rate. The G’ and G” values were derived from the 
linear viscoelastic regime of the frequency sweep between 0.1 to 10 rad/s at 5-10% strain at 25°C.  
2.9 Examine the disulfide bonds in PGM solution, bio-reducible mucus hydrogel 
and CF sputum  
CF sputum, PGM solution with different concentrations and bio-reducible mucus hydrogel with 
different pore size were papered using the original buffer and then diluted 10 times in 8M 
Guanidine Hydrochloride solution (Sigma-Aldrich). The diluted solutions were vortexed until 
became clear and homogeneous. The clear solutions were added 0.5M iodoacetamide (Sigma-
Aldrich) such that the final concentration is 10% (v/v) and incubation at room temperature for 1 
hour. 1M DTT was added such that the final concentration is 10% (v/v) and then the solutions 
were incubated at 37°C water bath for 2 hours. All small molecules were removed using premade 
zeba spin desalting columns. The column’s bottom closure was removed, and the cap was loosed. 
The columns were placed in a 1.5-2.0 mL collection tube, and then centrifuged at 1500 g for 1 
minute to remove storage solution. The columns were placed in a new tube. Sample was slowly 
added to the center if the compacted resin bed. The columns with sample were centrifuged at 1500 
g for 2 minutes to collect desalted sample. The serial dilutions of standard from 5mM L-cysteine 
(Sigma-Aldrich) were made. The 70 µL volume of 10 times diluted samples and standards were 
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added to plate. 70 µL of 2mM bromobimane (Sigma-Aldrich) were added to well and mixed. The 
plate was incubated at room temperature for 15 minutes and then read values by fluorescence (395 
excitation/ 490 emission) with auto scale option checked. All fluorometric measurements were 
performed using a microplate reader (BioTek Synergy Mx) [39].  
2.10 Examine the mucin concentration of bioreducible artificial mucus hydrogel 
and CF sputum 
The hydrogel sample was diluted with buffer solution containing 0.01M Na2HPO4 and 0.04% 
NaN3 at pH 7.4. Several dilutions of Mucin from bovine submaxillary glands (BSM) were made 
with filtered borate-phosphate buffer containing 0.3M borate, 0.3M phosphate dibasic at pH 8.0. 
0.5M Cyanoacetamide (Sigma-Aldrich) were made fresh. 0.1 mL Mucin solutions and sputum 
samples were mixed with 0.25 mL 0.5M Cyanoacetamide and 0.5 mL borate-phosphate buffer. 
The mixed solutions were incubated in oven for 3 hours at 100℃. The solutions were cooled by 
putting vials on ice for 15 min. Then solutions were aliquot into plate and read values by 
fluorescence (331 excitation/ 380 emission) with auto scale option checked [40], [41]. 
2.11 Bacteria Culture in Hydrogel 
To measure the bacteria growth in mucin from porcine stomach (PGM) and artificial bio-reducible 
hydrogel, 1 µl droplets (≈2000 CFU) P. aeruginosa were deposited on 15 µl of PGM (5% solids) 
and bio-reducible hydrogel (5% solids) of very MSD values in chambers. Before depositing P. 
aeruginosa in broth, 5% PGM and hydrogel, part of the stock bacteria suspension was collected, 
diluted with PBS, and plated on tryptic soy agar plates after serial dilution to test the starting 
number of P. aeruginosa. After that at 24, 48 h later, bacteria in PGM and hydrogel were collected, 
diluted with PBS containing 10mM DTT, and plated on tryptic soy plates after serial dilution. The 
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CFU (Colony-Forming Unit) of P. aeruginosa at different time point were counted after overnight 
incubation [29]. 
2.12 Statistical Analysis 
Statistical analysis and graphs were performed in Prism (GraphPad, San Diego, CA). Two sample 
comparisons were made using two-tailed, paired t-tests. All P values are two-sided and P < 0.05 











Results and Discussion  
3.1 Developing mucus-penetrating nanoparticles 
In our prior studies, we have shown that nanoparticles (NPs) with carboxylate and hydrophobic 
polystyrene (PSCOOH) cores are immobilized by mucus via muco-adhesion by hydrophobic and 
electrostatic interactions regardless of particle size [31], [42]. But polystyrene particles with 
hydrophilic coatings of high-density PEG are able to move through the pores in entangled mucin 
network by steric hindrance and thus, do not perturb biophysical properties of airway mucus. 
Therefore, these pegylated PSCOOH probes can measure the pores in the microstructure of mucus. 
We can infer about the size of the pores since the diffusion of particles is primarily blocked by 
steric interactions [43]. If size of NP < pore size, then particles are mobile, and if size of NP > pore 
size, then particles are immobilized. Our previous studies have established that 100 nm PSPEG 
particles are able to probe and be sensitive to the microstructure of mucus from patients with cystic 
fibrosis (CF) [21], [32], [43]. 
Furthermore, 100 nm PSPEG particles were developed and characterized along with PS 
counterparts by using dynamic light scattering and laser Doppler anemometry in this study. As 
shown in Table 1, we found that while the hydrodynamic diameters, polydispersity indices, and 
Log10(Median MSD t=1s) in H2O of size-matched PSPEG and PSCOOH were comparable, the ζ-
potentials (i.e. an indicative of particles surface charge) of PSPEG were near neutral charge unlike 















MSD t=1s) in 
H2O 
100 nm PSCOOH -35.7 ± 1.8 87.9 ± 3.8 0.1 ± 0.01 0.76 
100 nm PSPEG   -4.1 ± 0.2 98.0 ± 6.9 0.1 ± 0.01 0.79 
      α Measured in 10 mM NaCl at pH 7.4. 
      β Hydrodynamic diameter and polydispersity index measured by dynamic light scattering   
 
In our previous study, we have tested the stability of PSPEG particles in physiological lung fluid, 
and the results show that PSPEG particles are stable in physiological fluid. Since we made bio-
reducible mucus hydrogel based on PGM solution, we also evaluated the stability of PSPEG 
particles in pig gastric mucin (PGM) solution. As shown in Figure 1, while both PSCOOH and 
PSPEG retained their particle diameters at first 4 hours in 0.1 mg/mL PGM solution, only 













Figure 1. Stability of nanoparticles in mucin solution. Compared with PS particles which 
aggregated in mucin solution, PSPEG particles were stable in 0.1% mucin content after 6 hours of 





3.2 Microstructural properties of irreversible artificial hydrogels 
Irreversible mucin-based hydrogels were developed by crosslinking mucin fibers (PGM) using 
1000 Da SC-PEG-SC, which contain NHS ester groups at the side of two arms that react with 
amine groups in the mucin gel solution. After formulation (see Methods), the resulting bulk 
viscoelastic properties of the model mucus gel were confirmed qualitatively by an inversion test 
(Figure 2A). As evidenced by 100-nm PSPEG transport rates in mucin-based hydrogels at a fixed 
solids content of 5%, increasing the SC-PEG-SC concentration led to an increase in crosslinking 
density of mucin-based hydrogel, thereby reducing mesh pore size, as shown in Figure 2B. We 
next compared the Log10 (Median MSD τ=1s) of 100 nm PSPEG of irreversible hydrogel with that 
of CF sputum samples. We found that the Log10 (Median MSD τ=1s) varied among CF patients and 
median values of CF sputum are comparable with that of artificial irreversible hydrogels (Figure 
2C).  
 
Figure 2. Microstructure analysis of irreversible cross-linked mucin hydrogel and patients’ 
sputum sample. (A) Inversion test of a sample in an Eppendorf tube showing bulk viscoelastic 
properties of permanent cross-linked mucin-based hydrogel (containing 5% solids) and a CF 
sputum sample (right) at room temperature. Log10(Median MSD τ=1s) measured in (B) Irreversible 
mucin hydrogel (n = 3 replicates) by varying final concentrations of crosslinker and (C) patients’ 




We also investigated the impact of mucus-altering agent on microstructure of the artificial 
irreversible hydrogels, since our previous studies have shown the microstructural changes of CF 
sputum samples occur with mucolytic agents. Thus, in our study, we treated artificial irreversible 
hydrogel and CF sputum samples with TCEP and compared the mucolytic-mediated 
microstructure changes of them. As shown in Figure 3A & B, while TCEP was able to alter the 
microstructure of CF sputum mucus, this agent was unable to change the microstructure of 
artificial irreversible mucus hydrogel. Due to the limited change in Log10(Median MSD τ=1s) of 
artificial irreversible hydrogel by the mucus-altering agent, we turned to creating a bio-reducible 
mucus hydrogel to closely mimic reduction of CF sputum. 
 
Figure 3. The effect of mucolytic (TCEP) on microstructure of irreversible crosslinked mucin 
hydrogel and patients’ sputum sample. (A) Log10(Median MSD τ=1s) measured in irreversible 
mucin hydrogel with and without treatment with TCEP (n = 3 replicates) under varying final 
concentrations of cross-linker. (B) Log10(Median MSD τ=1s) measured in patients’ sputum sample 
with and without treatment with TCEP (***p < 0.001, two-tailed paired t-test, n = 3 replicates per 
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3.3 Microstructure properties of artificial bio-reducible hydrogels 
Considering that the mechanism of mucus-altering agents such as NAC and TCEP is breaking 
disulfide bonds in cysteines domain, and in turn reducing the size of mucin polymer chain, we 
chose another crosslinker to crosslink mucin with disulfide bridges, which is 1000 Da  OPSS-
PEG-OPSS, contains pyridyl disulfide ethyl at edge of two arms enabling to directly synthesize 
disulfide bonds via disulfide thiol interchange, and the byproduct Pyridine-2-thione is very stable. 
The artificial bio-reducible mucus hydrogel with increasing cross-linking density engineered by 
controlling the initial concentration of PGM solution, as shown in Figure 4A. We next compared 
the Log10(Median MSD τ=1s) of 100 nm PSPEG of bio-reducible hydrogel with that of CF sputum 
samples. We found that the Log10(Median MSD τ=1s) varied among CF patients’ sputum are 
comparable with that of artificial bio-reducible hydrogels (Figure 4B). The resulting bulk 
viscoelastic properties of the model mucus gel were confirmed qualitatively by an inversion test 
(Figure 4C).  
 
Figure 4. Microstructure analysis of bio-reducible cross-linked mucin hydrogel and patients’ 
sputum sample. Log10(Median MSD τ=1s) measured in (A) bio-reducible mucin hydrogel varied 
by final concentration of PGM (w/v %) and (B) patients’ sputum samples. Values represented as 
mean ± SEM. (C) Inversion test showing bulk viscoelastic properties of bio-reducible cross-linked 
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mucin-based hydrogel (containing 5% solids) and a CF sputum sample (right). (***p < 0.001, n = 
3) 
 
The mean pore size was also determined for artificial bio-reducible mucus hydrogel (Figure 5) 
from MSD values (Figure 4A). The impact of mucus-altering agent on microstructure of 
developed artificial bio-reducible hydrogels was also evaluated. We treated artificial bio-reducible 
hydrogel and CF sputum samples with two different mucolytics TCEP and NAC. As shown in 
Figure 6A & B, NAC was able to alter the microstructure of both bio-reducible hydrogel and CF 
sputum mucus with Log10(Median MSD τ=1s) around -1. However, no significant difference of 
microstructure changes was found in artificial bio-reducible hydrogel and CF mucus with 
Log10(Median MSD τ=1s) around 0 and -2. And as shown in Figure 6C & D, TCEP was able to 
alter the microstructure of artificial bio-reducible hydrogel and CF sputum mucus with 
Log10(Median MSD τ=1s) around -1 and -2. Based on these observations, TCEP appears more 
effective compared to NAC on reducing the viscoelasticity of mucus.  
























Figure 5. Microstructure analysis of bio-reducible cross-linked mucin hydrogel. Mean pore 
size measured in bio-reducible mucin hydrogel based on an obstruction scaling model[35], [44]. 
(**p < 0.01, ***p < 0.001, n = 3) 
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Figure 6. Characterization of microstructure change in bio-reducible cross-linked mucin-
based hydrogels. AH: artificial bio-reducible mucus hydrogel (A) Log10(Median MSD τ=1s) 
measured in bio-reducible mucin hydrogel with and without treatment with NAC. (B) 
Log10(Median MSD τ=1s) measured in patients’ samples with and without treatment with NAC. (C) 
Log10(Median MSD τ=1s) measured in bio-reducible mucin hydrogel with and without treatment 
with TCEP. (D) Log10(Median MSD τ=1s) measured in patients’ samples with and without 
treatment with TCEP. (***p < 0.001, two-tailed t-test, n = 3) 
 
Also, according to these data, the mucolytic-mediated microstructural changes of artificial bio-
reducible mucus hydrogel is comparable to what is observed in CF sputum. Of note, bulk rheology 
of bio-reducible mucus hydrogel with and without mucolytic treatment were also investigated 
(Figure 7A & B). We can see in figure A and B the Bulk elastic and viscous moduli significantly 
reduced upon mucolytic TCEP treatment in bio-reducible hydrogel with 180nm pore size, which 
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further confirmed the mucolytics responses of bio-reducible hydrogel in bulk size. And by 
comparing the storage and loss moduli with dash lines in figure which are literature values of CF 
sputum [45], we found that the bulk rheology of bio-reducible artificial mucus hydrogel is 
comparable to rheology of CF sputum.  
 
 
Figure 7. Bulk rheology of bio-reducible mucus hydrogel with and without mucolytic 
treatment. (A) Storage modulus of bio-reducible mucin hydrogel (B) Loss modulus of bio-
reducible mucin hydrogel. Values estimated as mean ± SEM from frequency sweep between 0.1 
to 1 rad/s along linear viscoelastic (LVE) regime with 5-10% strain. The dash lines are literature 
values of CF sputum’s storage and loss moduli [45].  Values shown as mean ± SEM along LVE. 
3.4 Biochemical properties of bio-reducible mucus hydrogel 
As mentioned above the solids content of bio-reducible hydrogel is 5%. In order to ensure that 
other biochemical components (mucin and cysteine contents) in bio-reducible hydrogel is 
comparable to those in CF patients’ sputum samples. The mucin and cysteine content in bio-
reducible hydrogel and CF sputum were quantitatively measured. The range of mucin content in 
bio-reducible hydrogel is from 15 mg/mL to 25 mg/mL (Figure 8A), which is comparable with 
the range of mucin content in CF sputum have shown in Figure 8B (10 mg/mL–25 mg/mL). 
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Similarly, the cysteine content in bio-reducible hydrogel is in the range of mucin content in CF 
sputum. (Figure 8C & D). 
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Figure 8. Biochemical measurements of Bio-reducible cross-linked mucin hydrogel and CF 
patients’ sample. AH: artificial bio-reducible mucin hydrogel (A) Mucin concentration in bio-
reducible mucin hydrogel with different pore size. (B) Mucin concentration in CF patients’ sputum 
samples. (C) Cysteines concentration in bio-reducible mucin hydrogel with different pore size. (D) 
Cysteines concentration in CF patients’ sputum samples. (A) and (B) A fluorescent assay using 
cyanoacetamide (CNA) shows that the concentration of mucin in artificial bio-reducible hydrogel 
is in the ranges of that in CF sputum (n = 3). (C) and (D) A fluorescent assay using dithiothreitol 
(DTT) and monobromobimane (mBBr) shows that the number of cysteines of artificial bio-
reducible hydrogel is in the ranges of that of CF sputum (n = 3). 
3.5 Bacteria growth in bio-reducible mucus hydrogel 
Based on previous studies, a vexing problem in CF pathogenesis has been to explain the high 
prevalence of Pseudomonas aeruginosa biofilms in CF airways and P. aeruginosa is the major 
pathogen infecting the CF lung. Thus, P. aeruginosa has been chosen in our study on whether 
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developed bio-reducible hydrogels are suitable for bacteria growth. P. aeruginosa grew and within 
24 h reached the stationary phase at 108 cfu/chamber for broth and 5% PGM solution (Figure 9A) 
served as control group. P. aeruginosa grew in bio-reducible hydrogel with 330 nm and 180 nm 
mean pore size reached the stationary phase at 108 cfu/chamber within 24 hours. P. aeruginosa 
grew in bio-reducible hydrogel with 650 nm mean pore size reached the stationary phase at 106 
cfu/chamber within 24 hours and achieve 107 cfu/chamber within 48 hours (Figure 9B). These 
two figures have shown that bio-reducible artificial mucus hydrogel does not undermine the 
intrinsic ability of bacterial cells to grow. 
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Figure 9. Growth of P. aeruginosa strain in different mucin-based models. (A) Bacterial 
growth curve in broth and 5% PGM. Approximately 2000 P. aeruginosa were deposited in broth 
and 5% PGM solution. Number of bacteria was counted at 0, 6, 24, 48 h intervals; n=3. (B) Growth 
curve of bacteria in bio-reducible mucin hydrogel with different pore size. Bacteria were counted 










On account of the complexity of microenvironment in CF airway mucus, it is hard for researchers 
to get deep understanding of behavior of bacteria and distribution of inflammatory cells. Although 
in previous study, mucus with high solids content from well-differentiated human airway cultures 
are used as model to investigate the microcolony development and neutrophil migration, the poor 
correlation between solids content and clinical status, FEV1 indicated that this model based solely 
on solids content potentially is lacking to to mimic CF airway mucus. We hypothesize that 
microstructural properties significantly correlate with clinical outcome in previous study. 
Thus, we have developed an artificial mucus hydrogel with defined pore size and solids content 
with PGM and different crosslinker to try to mimic CF airway mucus. By crosslinking PGM 
solution with SC-PEG-SC, we synthesized irreversible mucus hydrogel. Although the 
microstructures of irreversible mucus hydrogel are comparable with that of CF sputum, the 
mucolytic-mediated microstructural changes of irreversible hydrogel were not as significant as 
observed in CF sputum. After that, we developed bio-reducible artificial mucus hydrogel by 
crosslinking PGM with OPSS-PEG-OPSS. We demonstrated that the microstructure of bio-
reducible mucus hydrogel is comparable to that of CF airway mucus, and its mucolytic-mediated 
microstructural changes are same with what observed in CF sputum. We also evaluated the bulk 
rheology and rheology changes after mucolytic treatment, the result confirmed that the rheology 
of bio-reducible mucus hydrogel is comparable to that of CF sputum. We compared the mucin and 
cysteines content in bio-reducible hydrogel with those in CF sputum. These results have shown 
that the contents of mucin and cysteines in bio-reducible hydrogel were in the range of mucin and 
cysteines in CF sputum. Thus, based on these evaluations, bio-reducible artificial mucus hydrogel 
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has been validated and can serve as a model to mimic airway CF mucus to help us understand the 














After we evaluated the bio-reducible artificial hydrogel comprehensively, we can further use this 
model to understand the behavior of bacteria and distribution of inflammatory cells. Although 
Matsui, H et al. group have previously studied bacteria distribution in mucus with different solids 
content, we still know little about the relationship between microstructure of mucus and bacteria 
colony distribution.  By investigating the microcolony development of bacteria in bio-reducible 
hydrogel we could understand the effect of microstructure on bacterial microcolony development. 
And to explore whether the microstructure of hydrogel will affect neutrophil velocity and whether 
neutrophil would be trapped in hydrogel with small pore size, we will examine the neutrophil 
migration in bio-reducible hydrogel. We can further investigate the ability of neutrophil to capture 
bacteria in bio-reducible hydrogels with different pore size to examine the effect of microstructure 
of mucus on neutrophil-bacteria capture. 
Also, since there are some other diseases relating to mucus in other part of body, by altering the 
type of mucin to crosslink and controlling the ratio of crosslinker, we could develop an artificial 
mucus hydrogel model to mimic mucus in other part of our body, for example, gastrointestinal 
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RESEARCH EXPERIENCES    
The Effect of Cystic Fibrosis (CF) Sputum’s Microstructure on Bacteria Colonization and Neutrophil 
Migration  
                                                                                                                                              2/2018-Present                                                                                                                                                                              
• Developed the permanent and bio-reducible artificial mucus hydrogel to mimic the microstructure of CF 
patients’ sputum using mucin from porcine stomach (PGM) and crosslinkers  
• Engineered mucus-penetrating nanoparticles (MPP) by coating the fluorescent beads with PEG at high 
densities required to make particle surfaces resistant to muco-adhesion  
• Used MPP and conventional mucoadhesive nanoparticles (CP) as the probes, and performed fluorescent 
video microscopy experiments to track the motion of nanoparticles in models to evaluate the microstructure 
(MSD) of artificial mucus models and compared with CF sputum samples  
• Evaluated the biochemicals (mucin, cysteines) concentration of artificial mucus hydrogel and compared with 
these of CF sputum samples 
• Investigated the effect of mucolytics on artificial mucus hydrogel and compared it responsibility with that of 
CF sputum samples 
• Determined the effect of microstructure of mucus hydrogel on bacteria colonization by evaluating the bacteria 
growth and microcolony development of bacteria in mucus hydrogel with different microstructures, and tend 
to prove that microcolonies are greater in mucus hydrogel with smaller pore size 
• To determine the effect of microstructure of mucus on neutrophil migration by examining the neutrophil 
chemotaxis in gravitational and antigravitational directions in mucus hydrogel with different microstructures, 
and tend to prove that neutrophil migration will be hindered in mucus hydrogel with smaller pore size 
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• To determine the effect of microstructure of mucus on neutrophil-bacteria capture by investigating the 
survival of bacteria incubated with neutrophils in mucus hydrogel with different microstructures. 
 
Microstructural Changes in CF Sputum Correlate with Patient Lung Function over Longitudinal Time 
Points 
                                                                                                                                                      09/2017-Present                                                                                                                                                                              
• Engineered mucus-penetrating particles (MPP) using fluorescent beads with controlled particle diameters 
densely coated with PEG to make particle surfaces resistant to muco-adhesion  
• Compared those particles’ physicochemical properties with non-pegylated counterparts (which is called 
conventional particles (CP) in this study), and proved MPP were muco-inert, stable and non-adhesive to CF 
sputum 
• Quantified mucus solids content and measured the concentrations of mucin, DNA and cross-linked cysteine 
via well-established fluorometric assays, which led to the findings that individual sputum constituents 
collectively impacted on the microstructure of airway mucus   
• Correlated biophysical (i.e. mucus microstructure or MSD) and biochemical (i.e. solids content and 
concentration of cross-linked cysteine) properties of sputum samples with lung functions of CF patients, 
which were measured by spirometry (i.e. FEV1s) at the day of their clinical visit and sputum expectoration, and 
observed the trend of positive or negative correlations between FEV1s and MSD or solids content 
• Carried out a pilot longitudinal study to monitor the changes in sputum biophysical property (i.e. pore sizes 
or MSD) over subsequent clinical visits of CF patients, correlated the changes with their lung function 
changes, and concluded that our biophysical analysis of expectorated sputum may serve as a surrogate to 
monitor lung functions of CF patients over time  
• Examined the utility of MSD measurements for evaluating the efficacies and kinetics of mucus-altering 
therapeutic agents via a pilot study, and proved that treatment of sputum with TCEP could significantly 
increase the pore sizes at a final concentration of 5 mM 
• To investigate whether biophysical property, or perhaps biochemical properties, may provide a means to 
predict future exacerbation events among CF patients 
A Biochemical Analysis of Chronic Obstructive Pulmonary Disease (COPD) Sputum Samples for 
Determination of Predictive Factors 
                                                                                                                                                     10/2017-10/2018 
• Analyzed features (biophysical and biochemical properties of the COPD sputum) including MSD, mucin 
solid concentration, mucin concentration, DNA concentration, disulfide bond concentration, Neutrophils 
(%), Macrophages (%) and Lymphocytes (%) to examine variation and correlation of the data. And 
correlated to patients’ demographics. 
• Correlated biophysical (i.e. mucus microstructure or MSD) and biochemical (i.e. solids content, osmotic 
pressure and concentration of cross-linked cysteine) properties of sputum samples with lung functions of 
COPD patients, which were measured by spirometry (i.e. FEV1s) at the day of their clinical visit and sputum 
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expectoration, and observed the trend of positive or negative correlations between FEV1s and MSD or solids 
content 
• Examined the correlation between MSD and mucus solids, mucin content, DNA content and osmotic pressure 
and observed that there are obvious negative correlations with MSD and solids, osmotic pressure 
• The first and second principal components of the PCA suggest its best to select Mucus solids, DNA 
concentration and Mucin concentration as inputs for a ML model for classification of COPD exacerbation.   
Study about the Effect of Coated Protein Nanocages in Brain-Penetration and Doxorubicin Efficacy for 
Treatment of Aggressive Gliomas                                                                              01/2018-
10/2018                                                                                                                                                                             
• Tested the moving ability (MSD; an averaged square of distance travelled by an individual particle over a 
given time interval) of Ftn-CY3 and PEG-Ftn-CY3 particles in normal and tumor brain section.  
• The result shows that moving ability of Ftn-CY3 particles are increased with PEG coated, and the MSD value 
of Ftn-CY3 and PEG-Ftn-CY3 particles in tumor brain section is increased compared with normal brain 
section. 
Synthesis and Characterization of Metal-fiber Structured Cu-Zn-Al Hydrotaclcite-like Compounds  
                                                                                                                                                          02/2017-
06/2017                                                                                                                                                                              
• Combined merits of Layered Double Hydroxide (LDHs) and structured-supports together to develop metal-
fiber structured Cu-Zn-Al-LDHs/FeCrAl-fiber, which has strong capacity to enhance mass/heat transfer and 
optimize fluid dynamics via in-situ hydrothermal growth method  
• Optimized the preparation conditions of metal-fiber structured Cu-Zn-Al-LDHs/FeCrAl-fiber via adjusting 
support, pH value of solution, reaction temperature and reaction time  
Study of the Applications for Determination of Polyamines Based on Capillary Electrophoresis Combined 
with Electromembrane Extraction  
                                                                                                                               09/2015-05/2016                                                                                                                                                                                                                                                                                                             
• A capillary electrophoresis with capacitively coupled contactless conductivity detection (CE-C4D) method 
was developed for direct determination of polyamines, and the detection sensitivity was significantly 
improved based on electromembrane extraction (EME) 
• Ethanediamine and hexamethylendiamine are two diamine plastic restricted substances commonly existing 
in food contact materials and could be well separated from their aliphatic diamine homologs as well as the 
common inorganic cations within 25 min. 
• Under the optimum conditions, the highest enrichment factor of ethanediamine and hexamethylendiamine 
were 718-fold and 660-fold, respectively, and the limits of detection were both 0.04 ng/mL.  
• The research paper was published in the journal of Food Chemistry  
• (IF 4.052, http://dx.doi.org/10.1016/j.foodchem.2016.11.084) 
Catalysts Experiments                                                                                                                  07/2016-08/2016                                                                                                                                                                                                                                                                                                             
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• The research work focused on the introduction of the second metal to modify the performance of Pd catalyst. 
The Pd-In (indium) bimetallic catalysts with different ratio of Pd/In, i.e. Pd1In0.2, Pd1In0.4 and Pd1In0.6 (where 
1 and 0.6 represent the weight fraction of Pd and In in catalyst), were prepared with co-impregnation method. 
• The results suggest that the insertion of In component can isolate Pd active sites, i.e., geometric interaction, 
which reduces acetylene adsorbed on Pd-In bimetallic surface in bridged forms and leads to weakly π-
bonded acetylene on top sites of isolated Pd. 
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